This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Destiny Pharma Future Growth

Future criteria checks 0/6

Destiny Pharma's revenue and earnings are forecast to decline at 171.4% and 15.5% per annum respectively while EPS is expected to decline by 13.6% per annum.

Key information

-15.5%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate-171.4%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Jul 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:D89 - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-8N/AN/A1
12/31/2024N/A-6-6-52
12/31/20231-6-6-5N/A
9/30/20231-6-5-5N/A
6/30/20231-6-5-5N/A
3/31/20231-6-6-6N/A
12/31/20220-7-6-6N/A
9/30/20220-6-5-5N/A
6/30/20220-6-5-5N/A
3/31/20220-6-5-5N/A
12/31/20210-5-5-5N/A
9/30/20210-5-7-6N/A
6/30/20210-5-9-6N/A
3/31/20210-5-8-6N/A
12/31/20200-5-8-5N/A
9/30/20200-5-6-5N/A
6/30/20200-5-4-4N/A
3/31/20200-5-4-4N/A
12/31/20190-5-5-5N/A
9/30/20190-5-5-5N/A
6/30/2019N/A-5-6-6N/A
3/31/2019N/A-5-5-5N/A
12/31/2018N/A-5-5-5N/A
9/30/2018N/A-5-4-4N/A
6/30/2018N/A-4-3-3N/A
3/31/2018N/A-4-3-3N/A
12/31/2017N/A-3-2-2N/A
9/30/2017N/A-2N/A-2N/A
6/30/2017N/A-2N/A-1N/A
3/31/2017N/A-1N/A-1N/A
12/31/2016N/A-1N/A-1N/A
12/31/2015N/A-1N/A-1N/A
12/31/2014N/A-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: D89 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: D89 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: D89 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: D89 is forecast to have no revenue next year.

High Growth Revenue: D89 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if D89's Return on Equity is forecast to be high in 3 years time


Discover growth companies